 For the past decade, efforts to increase overall survival and progression-free survival for patients with high-risk pediatric and young adult tumors, have evaluated the use of high-dose chemotherapy and hematopoietic stem cell transplantation HSCT. The proportion of patients who enter a complete remission with HSCT is high, ranging from 81 to 90. While autologous HSCT renders a large proportion of patients temporarily disease-free, relapse develops in the majority of patients. 